×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMAB – i-mab - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/29
11:05 pm
imab
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Neutral
Report
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
10/29
11:15 am
imab
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Low
Report
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
10/28
10:00 am
imab
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
10/27
10:07 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/27
10:07 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/27
08:06 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
10/24
08:06 am
imab
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
10/23
10:00 am
imab
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/31
06:07 am
imab
Form 6-K NovaBridge Biosciences For: Oct 31
Neutral
Report
Form 6-K NovaBridge Biosciences For: Oct 31
10/30
06:04 am
imab
Form 6-K NovaBridge Biosciences For: Oct 29
Neutral
Report
Form 6-K NovaBridge Biosciences For: Oct 29
10/30
06:00 am
imab
Form 424B3 NovaBridge Biosciences
Neutral
Report
Form 424B3 NovaBridge Biosciences
10/29
04:05 pm
imab
Form 6-K NovaBridge Biosciences For: Oct 29
Low
Report
Form 6-K NovaBridge Biosciences For: Oct 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/25
I-Mab Announces Upcoming Participation at March Conferences
15.1%
4/29 Form 20-F I-Mab For: Dec 31 14.5%
3/27 Form 6-K I-Mab For: Mar 27 8.2%
4/2 I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China 7.5%
3/13 I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) 7.2%
3/30 Form 6-K I-Mab For: Mar 30 4.0%
4/17 Form 6-K I-Mab For: Apr 17 3.9%
4/15 I-Mab (IMAB) Investor Presentation - Slideshow [Seeking Alpha] 3.3%
2/10 I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering 1.6%
4/24 I-Mab Announces Upcoming Participation at May Conferences 0.9%
4/29 Form 20-F I-Mab For: Dec 31 14.5%
3/27 Form 6-K I-Mab For: Mar 27 8.2%
4/2 I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China 7.5%
3/13 I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) 7.2%
3/30 Form 6-K I-Mab For: Mar 30 4.0%
4/17 Form 6-K I-Mab For: Apr 17 3.9%
4/15 I-Mab (IMAB) Investor Presentation - Slideshow [Seeking Alpha] 3.3%
2/10 I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering 1.6%
4/24 I-Mab Announces Upcoming Participation at May Conferences 0.9%
TOP News Decliners
3/13
Form 6-K I-Mab For: Mar 13
-15.9%
1/17 I-MAB Announces Pricing of U.S. Initial Public Offering -15.3%
3/30 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea -7.4%
4/6 Form 6-K I-Mab For: Apr 06 -5.7%
4/6 I-Mab Announces Upcoming Participation at April Conferences -4.9%
3/11 I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020 -3.9%
2/14 Form SEC STAFF LETTER I-Mab -3.0%
2/12 Phoenix Tree Holdings Limited (NASDAQ: IMAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. -1.6%
3/23 Form 6-K I-Mab For: Mar 23 -1.3%
4/28 Form 6-K I-Mab For: Apr 28 -0.6%
1/17 I-MAB Announces Pricing of U.S. Initial Public Offering -15.3%
3/30 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea -7.4%
4/6 Form 6-K I-Mab For: Apr 06 -5.7%
4/6 I-Mab Announces Upcoming Participation at April Conferences -4.9%
3/11 I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020 -3.9%
2/14 Form SEC STAFF LETTER I-Mab -3.0%
2/12 Phoenix Tree Holdings Limited (NASDAQ: IMAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. -1.6%
3/23 Form 6-K I-Mab For: Mar 23 -1.3%
4/28 Form 6-K I-Mab For: Apr 28 -0.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: